Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

Summary

The study aims to assess the potential benefit and evaluate the safety and tolerability of a single subcutaneous (SC) dose of VIB7734 in hospitalized patients with documented infection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) with pulmonary involvement. Subjects will be administered a single dose of VIB7734 injected under the skin, assessed for efficacy for 28 days and followed for an additional 42 days.

Timeline

Start

2020-08-28

Primary completion

2021-04-08

Completion

2021-05-19

Outcome

Outcome not reported

Stopped: “Study met predefined futility criteria for efficacy endpoints.”

Drugs

Indications